Lilly Eyes India for Mounjaro Manufacturing: CEO Hints at Expansion Plans

Eli Lilly's CEO David Ricks has hinted at the possibility of manufacturing the blockbuster drug Mounjaro in India. In an exclusive interview with CNBC-TV18, Ricks expressed openness to partnerships with Indian companies for both marketing and potentially producing the anti-diabetes and weight loss medication. This development comes just days after Mounjaro's launch in India at a fraction of its US price. Ricks emphasized Lilly's philosophy of embracing partnerships globally, suggesting a strategic move to leverage India's pharmaceutical expertise. The potential manufacturing shift aligns with Lilly's recent $4.5 billion investment in expanding its production capabilities and could significantly impact the drug's accessibility in the rapidly growing Indian market.

 

Source: CNBC-TV18, Economic Times